ASH 2022 | HD21: treatment-related morbidity in patients with Hodgkin lymphoma treated with BrECADD vs eBEACOPP
Peter Borchmann, MD, University Hospital Cologne, Cologne, Germany, discusses the results of HD21 (NCT02661503), a Phase III study comparing the tolerability of the standard of care positron emission tomography (PET)-guided escalated bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone (eBEACOPP) against a new modified regimen with brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, dexamethasone (BrECADD). Prof. Borchmann explains how the new regimen reduced treatment-related morbidity (TRMB) and overall toxicity including neuropathy, gonadotoxicity, and reduced need for both red blood cell and platelet transfusions. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
